# Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma

> **NCT03994705** · PHASE1 · TERMINATED · sponsor: **Cartesian Therapeutics** · enrollment: 20 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** Descartes-11
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT03994705
- **Lead sponsor:** Cartesian Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-08-01
- **Primary completion:** 2021-05-27
- **Final completion:** 2021-06-11
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Phase 1 enrollment completed. Further clinical development terminated.
- **Last updated:** 2025-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03994705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03994705, "Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03994705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*